摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2,3-difluorophenyl)morpholine | 1424273-41-5

中文名称
——
中文别名
——
英文名称
4-(2,3-difluorophenyl)morpholine
英文别名
——
4-(2,3-difluorophenyl)morpholine化学式
CAS
1424273-41-5
化学式
C10H11F2NO
mdl
——
分子量
199.2
InChiKey
ISDCMHWBZWRSAD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    吗啉1,2,3-三氟苯potassium carbonate 作用下, 以 N-甲基吡咯烷酮 为溶剂, 反应 2.5h, 以72%的产率得到4-(2,3-difluorophenyl)morpholine
    参考文献:
    名称:
    Microwave-assisted amination from fluorobenzenes without catalyst and strong base
    摘要:
    A facile and versatile amination of fluorobenzenes has been developed in good to excellent yields under microwave irradiation in N-methylpyrrolidinone (NMP) without strong base and catalyst. The presence of additional halogen atom(s) enhanced the leaving ability of fluorine and meta fluorine gave higher activation than the ortho. It is remarkable that 1,2,3-trifluorobenzene, 1,2,4-trifluorobenzene and 1,2,4,5-tetrafluorobenzene can produce the regioselective mono-substituted products. (C) 2012 Elsevier B.V. All rights reserved.
    DOI:
    10.1016/j.jfluchem.2012.12.001
点击查看最新优质反应信息

文献信息

  • OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS
    申请人:Kadereit Dieter
    公开号:US20110190490A1
    公开(公告)日:2011-08-04
    The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R 1 , R 2 and R 3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    本发明涉及式I的噁唑嘧啶化合物,其中A、R1、R2和R3如权利要求所示。式I的化合物调节Edg-1受体的活性,特别是该受体的激动剂,并且可用于治疗动脉粥样硬化、心力衰竭或外周动脉闭塞性疾病等疾病。本发明还涉及制备式I的化合物的方法,它们的用途,特别是作为药物中的活性成分,以及包含它们的药物组合物。
查看更多